Former Senator's Pancreatic Cancer Trial Shows Major Progress

When former U.S. Senator Ben Sasse learned he had metastatic pancreatic cancer last December, doctors gave him three to four months to live. Today, he's celebrating what he calls "both quantity and quality of life" thanks to a clinical trial testing a revolutionary new drug.

Sasse's journey began last October with severe back pain that would double him over. Working on a farm growing up, he knew the difference between normal aches and something seriously wrong. Blood tests came back normal, but scans revealed the devastating truth: tumors throughout his torso and a significant mass in his pancreas.

The diagnosis came the day before his child's college graduation. As a Christian, Sasse found comfort in his faith, but he also chose action. Within days, he visited MD Anderson and Memorial Sloan Kettering to explore every possible option for survival.

Traditional chemotherapy offered little hope for his advanced cancer. But Dr. Eileen O'Reilly at Memorial Sloan Kettering, described to Sasse as the nation's top pancreatic cancer specialist, suggested something different: an early phase trial for daraxonrasib, a next-generation targeted therapy from Revolution Medicines.

The drug has delivered results that feel miraculous to Sasse. His CA 19-9 levels, a key blood marker for pancreatic cancer, plummeted from over 8,000 to 374. His tumor volume has shrunk by roughly 60 percent, and the debilitating pain that once consumed 70 percent of his waking hours has dramatically decreased.

The journey hasn't been easy. When he first started treatment, the tumor "fought back" with intense pain and massive facial bleeding that required a pause for antibiotics. But his medical team reassured him that the tumor's aggressive response actually signaled the drug was working.

Why This Inspires

Pancreatic cancer has long been one of medicine's toughest challenges, with survival rates that offer little hope. Sasse's response to daraxonrasib represents more than one man's fight for life. It's early evidence that science is finally making headway against a disease that has defeated countless patients and frustrated doctors for decades.

Revolution Medicines announced positive results from their Phase 3 trial this week, showing patients on daraxonrasib lived a median of 13.2 months compared to 6.7 months on chemotherapy. Experts are confident the drug will gain approval, offering new hope to thousands of families facing similar diagnoses.

For Sasse, participating in the trial means fighting for every day with his wife and children while potentially helping future patients. He's already lived longer than his initial prognosis, and each week brings more encouraging news about his tumor markers and quality of life.

The breakthrough couldn't come soon enough for the pancreatic cancer community, which has seen few major treatment advances in decades.